This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
1 S Reynolds & T Quinn (2010) Setting the stage: current state of affairs and major challenges. Clin Infect Dis 50, Suppl. 3, S71–S76.
5 MP de Béthune (2010) Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989–2009). Antiviral Res 85, 75–90.
8 E De Clercq (1998) The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res 38, 153–179.
9 TN Kakuda (2000) Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 22, 685–708.
11 GH Wynn , MJ Zapor , BH Smith , et al. (2004) Antiretrovirals, part 1: overview, history, and focus on protease inhibitors. Psychosomatics 45, 262–270.
12 ML Greenberg & N Cammack (2004) Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 54, 333–340.
15 MP Dubé , DL Johnson , JS Currier , et al. (1997) Protease inhibitor-associated hyperglycaemia. Lancet 350, 713–714.
17 RL Hengel , NB Watts & JL Lennox (1997) Benign symmetric lipomatosis associated with protease inhibitors. Lancet 350, 1596.
19 R Viraben & C Aquilina (1998) Indinavir-associated lipodystrophy. AIDS 12, F37–F39.
24 SW Worm , N Friis-Møller , M Bruyand , et al. (2010) High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS 24, 427–435.
25 K Samaras , H Wand , M Law , et al. (2007) Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria. Diabetes Care 30, 113–119.
28 TT Brown , SR Cole , X Li , et al. (2005) Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicenter AIDS Cohort Study. Arch Intern Med 165, 1179–1184.
32 K Mondy , E Overton , J Grubb , et al. (2007) Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis 44, 726–734.
34 S Matetzky , M Domingo , S Kar , et al. (2003) Acute myocardial infarction in human immunodeficiency virus-infected patients. Arch Intern Med 163, 457–460.
37 N Friis-Møller , R Thiébaut , P Reiss , et al. (2010) Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 17, 491–501.
38 G Guaraldi , S Zona , N Alexopoulos , et al. (2009) Coronary aging in HIV-infected patients. Clin Infect Dis 49, 1756–1762.
44 S Tsiodras , K-A Poulia , M Yannakoulia , et al. (2009) Adherence to Mediterranean diet is favorably associated with metabolic parameters in HIV-positive patients with the highly active antiretroviral therapy-induced metabolic syndrome and lipodystrophy. Metabolism 58, 854–859.
46 DL Jacobson , AM Tang , D Spiegelman , et al. (2006) Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr 43, 458–466.
47 ME Sobieszczyk , DR Hoover , K Anastos , et al. (2008) Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 48, 272–280.
48 PC Tien , SR Cole , CM Williams , et al. (2003) Incidence of lipoatrophy and lipohypertrophy in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 34, 461–466.
49 A Norris & HM Dreher (2004) Lipodystrophy syndrome: the morphologic and metabolic effects of antiretroviral therapy in HIV infection. J Assoc Nurses AIDS Care 15, 46–64.
50 P Benn , C Ruff , J Cartledge , et al. (2003) Overcoming subjectivity in assessing facial lipoatrophy: is there a role for three-dimensional laser scans? HIV Med 4, 325–331.
52 FDA Boufassa , AS Lascaux , L Meyer , et al. (2001) Lipodystrophy in 685 HIV-1-treated patients: influence of antiretroviral treatment and immunovirological response. HIV Clin Trials 2, 339–345.
54 M Galli , A Cozzi-Lepri , AL Ridolfo , et al. (2002) Incidence of adipose tissue alterations in first-line antiretroviral therapy: The LipoICoNa Study. Arch Intern Med 162, 2621–2628.
55 M Galli , F Veglia , G Angarano , et al. (2003) Gender differences in antiretroviral drug-related adipose tissue alterations: women are at higher risk than men and develop particular lipodystrophy patterns. J Acquir Immune Defic Syndr 34, 58–61.
59 EM Mutimura , AP Stewart , PMD Rheeder , et al. (2007) Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 46, 451–455.
60 A Nguyen , A Calmy , V Schiffer , et al. (2008) Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000–2006. HIV Med 9, 142–150.
63 T Saint-Marc , M Partisani , I Poizot-Martin , et al. (2000) Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 14, 37–49.
64 R Thiébaut , V Daucourt , P Mercié , et al. (2000) Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Clin Infect Dis 31, 1482–1487.
65 KA Lichtenstein , DJ Ward , AC Moorman , et al. (2001) Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 15, 1389–1398.
66 KV Heath , J Singer , MV O'Shaughnessy , et al. (2002) Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy. J Acquir Immune Defic Syndr 31, 211–217.
69 KA Lichtenstein , KM Delaney , C Armon , et al. (2003) Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 32, 48–56.
71 J van Griensven , L De Naeyer , T Mushi , et al. (2007) High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans R Soc Trop Med Hyg 101, 793–798.
72 S Walmsley , A Cheung , G Fantus , et al. (2008) A prospective study of body fat redistribution, lipid, and glucose parameters in HIV-infected patients initiating combination antiretroviral therapy. HIV Clin Trials 9, 314–323.
73 D Jevtovic , G Dragovic , D Salemovic , et al. (2009) The metabolic syndrome, an epidemic among HIV-infected patients on HAART. Biomed Pharmacother 63, 337–342.
74 S Mercier , NFN Gueye , A Cournil , et al. (2009) Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case–control study. J Acquir Immune Defic Syndr 51, 224–230.
76 C Gervasoni , AL Ridolfo , G Trifiro , et al. (1999) Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 13, 465–471.
78 KV Heath , RS Hogg , KJ Chan , et al. (2001) Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 15, 231–239.
81 M Savès , F Raffi , J Capeau , et al. (2002) Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 34, 1396–1405.
82 A Carr , S Emery , M Law , et al. (2003) An objective case definition of lipodystrophy in HIV-infected adults: a case–control study. Lancet 361, 726–735.
84 J Fellay , B Ledergerber , E Bernasconi , et al. (2001) Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 358, 1322–1327.
87 C Jericó , H Knobel , M Montero , et al. (2005) Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care 28, 132–137.
88 A Elgalib , M Aboud , R Kulasegaram , et al. (2011) The assessment of metabolic syndrome in UK patients with HIV using two different definitions: CREATE 2 study. Curr Med Res Opin 27, 63–69.
90 E Gkrania-Klotsas & A-E Klotsas (2007) HIV and HIV treatment: effects on fats, glucose and lipids. Br Med Bull 84, 49–68.
93 SH Han , J Zhou , S Saghayam , et al. (2011) Prevalence of and risk factors for lipodystrophy among HIV-infected patients receiving combined antiretroviral treatment in the Asia-Pacific region: results from the TREAT Asia HIV Observational Database (TAHOD). Endocr J 58, 475–484.
94 C Wanke , B Polsky & D Kotler (2002) Guidelines for using body composition measurement in patients with human immunodeficiency virus infection. AIDS Patient Care STDS 16, 375–388.
95 A Carr , M Law &
HIV Lipodystrophy Case Definition Study Group
(2003) An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr 33, 571–576.
96 J Fontdevila , JM Serra-Renom , M Raigosa , et al. (2008) Assessing the long-term viability of facial fat grafts: an objective measure using computed tomography. Aesthet Surg J 28, 380–386.
98 A Carr , K Samaras , A Thorisdottir , et al. (1999) Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353, 2093–2099.
99 S Safrin & C Grunfeld (1999) Fat distribution and metabolic changes in patients with HIV infection. AIDS 13, 2493–2505.
105 S Grinspoon & A Carr (2005) Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 352, 48–62.
106 DL Jacobson , T Knox , D Spiegelman , et al. (2005) Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis 40, 1837–1845.
107 KD Miller , E Jones , JA Yanovski , et al. (1998) Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 351, 871–875.
108 WL Dinges , D Chen , PG Snell , et al. (2005) Regional body fat distribution in HIV-infected patients with lipodystrophy. J Investig Med 53, 15–25.
109 JC Lo , K Mulligan , VW Tai , et al. (1998) “Buffalo hump” in men with HIV-1 infection. Lancet 351, 867–870.
111 G Guaraldi , G Orlando , N Squillace , et al. (2007) Prevalence of and risk factors for pubic lipoma development in HIV-infected persons. J Acquir Immune Defic Syndr 45, 72–76.
114 C Grunfeld , DP Kotler , JK Shigenaga , et al. (1991) Circulating interferon-α levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 90, 154–162.
116 J Tomažič , A Silič , P Karner , et al. (2004) Lipodystrophy and metabolic abnormalities in Slovenian HIV-infected patients. Wien Klin Wochenschr 116, 755–759.
117 OA Lesi , KS Soyebi & CN Eboh (2009) Fatty liver and hyperlipidemia in a cohort of HIV-positive Africans on highly active antiretroviral therapy. J Natl Med Assoc 101, 151–155.
118 N Friis-Møller , R Weber , P Reiss , et al. (2003) Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. AIDS 17, 1179–1193.
120 D Periard , A Telenti , P Sudre , et al. (1999) Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 100, 700–705.
121 F van Leth , P Phanuphak , E Stroes , et al. (2004) Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 1, e19.
122 R Jones , S Sawleshwarkar , C Michailidis , et al. (2005) Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med 6, 396–402.
125 BZ Monnerat , C Cerutti Junior , SC Caniçali , et al. (2008) Clinical and biochemical evaluation of HIV-related lipodystrophy in an ambulatory population from the Hospital Universitário Cassiano Antonio de Morais, Vitória, ES, Brazil. Braz J Infect Dis 12, 364–368.
126 H Pernerstorfer-Schoen , B Jilma , A Perschler , et al. (2001) Sex differences in HAART-associated dyslipidaemia. AIDS 15, 725–734.
128 AS Foulkes , DA Wohl , I Frank , et al. (2006) Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med 3, e52.
129 M Guardiola , R Ferré , J Salazar , et al. (2006) Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T → C gene variation. Clin Chem 52, 1914–1919.
132 D Nolan , C Moore , A Castley , et al. (2003) Tumour necrosis factor-α gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS 17, 121–123.
133 E Tarr Philip , P Taffé , G Bleiber , et al. (2005) Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis 191, 1419–1426.
134 NN Abourizk , RW Lyons & GM Madden (1993) Transient state of NIDDM in a patient with AIDS. Diabetes Care 16, 931–933.
135 RA Bradbury & K Samaras (2008) Antiretroviral therapy and the human immunodeficiency virus – improved survival but at what cost? Diabetes Obes Metab 10, 441–450.
136 JA Eastone & CA Decker (1997) New-onset diabetes mellitus associated with use of protease inhibitor. Ann Intern Med 127, 948.
137 F Visnergarwala , KL Krause & DM Musher (1997) Severe diabetes associated with protease inhibitors. Ann Intern Med 127, 947.
138 S van Dieren , JWJ Beulens , YT van der Schouw , et al. (2010) The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil 17, Suppl. 1, s3–s8.
139 G Danaei , MM Finucane , Y Lu , et al. (2011) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 378, 31–40.
140 A Carr , J Hudson , J Chuah , et al. (2001) HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS 15, 1811–1822.
141 MP Dubé , RA Parker , P Tebas , et al. (2005) Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 19, 1807–1818.
143 GA Lee , T Seneviratne , MA Noor , et al. (2004) The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 18, 641–649.
144 H Woerle , PR Mariuz , C Meyer , et al. (2003) Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 52, 918–925.
145 PC Tien , MF Schneider , SR Cole , et al. (2007) Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 21, 1739–1745.
147 DA Wohl , G McComsey , P Tebas , et al. (2006) Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 43, 645–653.
149 ER de Arruda Junior , HR Lacerda , LCRV Moura , et al. (2010) Risk factors related to hypertension among patients in a cohort living with HIV/AIDS. Braz J Infect Dis 14, 281–287.
150 FR Sattler , D Qian , S Louie , et al. (2001) Elevated blood pressure in subjects with lipodystrophy. AIDS 15, 2001–2010.
152 SS Franklin (2008) Beyond blood pressure: arterial stiffness as a new biomarker of cardiovascular disease. J Am Soc Hypertens 2, 140–151.
153 MGA van Vonderen , YM Smulders , CDA Stehouwer , et al. (2009) Carotid intima-media thickness and arterial stiffness in HIV-infected patients: the role of HIV, antiretroviral therapy, and lipodystrophy. J Acquir Immune Defic Syndr 50, 153–161.
155 EC Seaberg , L Benning , AR Sharrett , et al. (2010) Association between human immunodeficiency virus infection and stiffness of the common carotid artery. Stroke 41, 2163–2170.
156 SS Shankar & MP Dubé (2004) Clinical aspects of endothelial dysfunction associated with human immunodeficiency virus infection and antiretroviral agents. Cardiovasc Toxicol 4, 261–269.
157 JH Stein , MA Klein , JL Bellehumeur , et al. (2001) Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104, 257–262.
159 FJ Torriani , L Komarow , RA Parker , et al. (2008) Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 52, 569–576.
160 C Lefèvre , M Auclair , F Boccara , et al. (2010) Premature senescence of vascular cells is induced by HIV protease inhibitors. Arterioscler Thromb Vasc Biol 30, 2611–2620.
161 B Coll , S Parra , C Alonso-Villaverde , et al. (2006) HIV-infected patients with lipodystrophy have higher rates of carotid atherosclerosis: the role of monocyte chemoattractant protein-1. Cytokine 34, 51–55.
162 L Calza , R Manfredi , D Pocaterra , et al. (2008) Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy. J Infect 57, 16–32.
163 RC Kaplan , LA Kingsley , SJ Gange , et al. (2008) Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 22, 1615–1624.
164 K Henry , H Melroe , J Huebsch , et al. (1998) Severe premature coronary artery disease with protease inhibitors. Lancet 351, 1328.
166 SA Bozzette , CF Ake , HK Tam , et al. (2003) Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348, 702–710.
168 G Barbaro , G Di Lorenzo , A Cirelli , et al. (2003) An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretrovial therapy. Clin Ther 25, 2405–2418.
169 JE Mallewa , SP Higgins , S Garbett , et al. (2009) Cardiovascular disease risk management in HIV patients, experiences from Greater Manchester. Int J STD AIDS 20, 425–426.
170 C Alvarez , R Salazar , J Galindez , et al. (2010) Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America. Braz J Infect Dis 14, 256–263.
171 JJ Schafer , WR Short & KE Squires (2010) Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virus. Pharmacotherapy 30, 1072–1083.
172 A Martin , J Amin , D Cooper , et al. (2010) Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. AIDS 24, 2657–2663.
177 N Friis-Møller & SW Worm (2007) Editorial commentary: can the risk of cardiovascular disease in HIV-infected patients be estimated from conventional risk prediction tools? Clin Infect Dis 45, 1082–1084.
178 M May , JA Sterne , M Shipley , et al. (2007) A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men. Int J Epidemiol 36, 1309–1318.
179 E Hammond , E McKinnon & D Nolan (2010) Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences. Clin Infect Dis 51, 591–599.
180 JA Johnson , JB Albu , ES Engelson , et al. (2004) Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am J Physiol Endocrinol Metab 286, E261–E271.
184 M Sievers , UA Walker , K Sevastianova , et al. (2009) Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse transcriptase inhibitor-associated lipodystrophy. J Infect Dis 200, 252–262.
185 J-P Bastard , M Maachi , JT van Nhieu , et al. (2002) Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87, 2084–2089.
187 J Kovsan , R Ben-Romano , SC Souza , et al. (2007) Regulation of adipocyte lipolysis by degradation of the perilipin protein. J Biol Chem 282, 21704–21711.
189 A Rudich , R Ben-Romano , S Etzion , et al. (2005) Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors. Acta Physiol Scand 183, 75–88.
190 HH Zhang , M Halbleib , F Ahmad , et al. (2002) Tumor necrosis factor-α stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes 51, 2929–2935.
191 M Rydén , E Arvidsson , L Blomqvist , et al. (2004) Targets for TNF-α-induced lipolysis in human adipocytes. Biochem Biophys Res Commun 318, 168–175.
192 D Adler-Wailes , EL Guiney , J Koo , et al. (2008) Effects of ritonavir on adipocyte gene expression: evidence for a stress-related response. Obesity 16, 2379–2387.
195 A Körner , M Wabitsch , B Seidel , et al. (2005) Adiponectin expression in humans is dependent on differentiation of adipocytes and down-regulated by humoral serum components of high molecular weight. Biochem Biophys Res Commun 337, 540–550.
196 M Pacenti , L Barzon , F Favaretto , et al. (2006) Microarray analysis during adipogenesis identifies new genes altered by antiretroviral drugs. AIDS 20, 1691–1705.
198 K Sevastianova , J Sutinen , K Kannisto , et al. (2008) Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy. Am J Physiol Endocrinol Metab 295, E85–E91.
204 G Birkus , MJM Hitchcock & T Cihlar (2002) Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 46, 716–723.
206 UA Walker , B Setzer & N Venhoff (2002) Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 16, 2165–2173.
207 E Ribera , JC Paradiñeiro , A Curran , et al. (2008) Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST Study). HIV Clin Trials 9, 407–417.
210 M Sension , JL de Andrade Neto , B Grinsztejn , et al. (2009) Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir. J Acquir Immune Defic Syndr 51, 153–162.
214 C Fichtenbaum , JG Gerber , SL Rosenkranz , et al. (2002) Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 16, 569–577.
215 T Feldt , M Oette , A Kroidl , et al. (2006) Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome. Infection 34, 55–61.
216 JM Raboud , C Diong , A Carr , et al. (2010) A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy. HIV Clin Trials 11, 39–50.
218 JPH van Wijk , AIM Hoepelman , EJP de Koning , et al. (2011) Differential effects of rosiglitazone and metformin on postprandial lipemia in patients with HIV-lipodystrophy. Arterioscler Thromb Vasc Biol 31, 228–233.
219 I Jiménez-Nácher , E Alvarez , J Morello , et al. (2011) Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients. Expert Opin Drug Metab Toxicol 7, 457–477.
220 E Martínez (2011) Disorders of fat partitioning in treated HIV-infection. Best Prac Res Clin Endocrinol Metab 25, 415–427.
222 BM Psaty & CD Furberg (2007) Rosiglitazone and cardiovascular risk. N Engl J Med 356, 2522–2524.
223 CS Hultman , LE McPhail , JH Donaldson , et al. (2007) Surgical management of HIV-associated lipodystrophy: role of ultrasonic-assisted liposuction and suction-assisted lipectomy in the treatment of lipohypertrophy. Ann Plas Surg 58, 255–263.
224 A Warren & LJ Borud (2008) Excisional lipectomy for HIV-associated cervicodorsal lipodystrophy. Aesthet Surg J 28, 147–152.
226 L Skeie , H Bugge , A Negaard , et al. (2010) Large particle hyaluronic acid for the treatment of facial lipoatrophy in HIV-positive patients: 3-year follow-up study. HIV Med 11, 170–177.
227 C Dollfus , S Blanche , N Trocme , et al. (2009) Correction of facial lipoatrophy using autologous fat transplants in HIV-infected adolescents. HIV Med 10, 263–268.
228 P Narciso , R Bucciardini , V Tozzi , et al. (2009) Immediate versus delayed surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy: a randomized open-label study. AIDS Res Hum Retroviruses 25, 979–987.
229 G Guaraldi , N Squillace , D De Fazio , et al. (2009) Heterologous fat transplantation for the treatment of HIV-related facial lipoatrophy. Ann Intern Med 150, 61–63.
230 L Terry , E Sprinz , R Stein , et al. (2006) Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy. Med Sci Sports Exerc 38, 411–417.
231 R Roubenoff , L Weiss , A McDermott , et al. (1999) A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS 13, 1373–1375.
233 KE Yarasheski & R Roubenoff (2001) Exercise treatment for HIV-associated medical and anthropomorphic complications. Exerc Sport Sci Rev 29, 170–174.
234 S Fillipas , CL Cherry , F Cicuttini , et al. (2010) The effects of exercise training on metabolic and morphological outcomes for people living with HIV: a systematic review of randomised controlled trials. HIV Clin Trials 11, 270–282.
237 B Lindegaard , T Hansen , T Hvid , et al. (2008) The effect of strength and endurance training on insulin sensitivity and fat distribution in human immunodeficiency virus-infected patients with lipodystrophy. J Clin Endocrinol Metab 93, 3860–3869.
238 C Hadigan (2003) Dietary habits and their association with metabolic abnormalities in human immunodeficiency virus-related lipodystrophy. Clin Infect Dis 37, Suppl. 2, S101–S104.
239 A Gavrila , S Tsiodras , J Doweiko , et al. (2003) Exercise and vitamin E intake are independently associated with metabolic abnormalities in human immunodeficiency virus-positive subjects: a cross-sectional study. Clin Infect Dis 36, 1593–1601.
240 MJ Batterham , R Garsia & PA Greenop (2000) Dietary intake, serum lipids, insulin resistance and body composition in the era of highly active antiretroviral therapy ‘Diet FRS Study’. AIDS 14, 1839–1843.
241 K Samaras , H Wand , M Law , et al. (2009) Dietary intake in HIV-infected men with lipodystrophy: relationships with body composition, visceral fat, lipid, glucose and adipokine metabolism. Curr HIV Res 7, 454–461.
242 A Barrios , F Blanco , T Garcia-Benayas , et al. (2002) Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia. AIDS 16, 2079–2081.
244 R Roubenoff , H Schmitz , L Bairos , et al. (2002) Reduction of abdominal obesity in lipodystrophy associated with human immunodeficiency virus infection by means of diet and exercise: case report and proof of principle. Clin Infect Dis 34, 390–393.
247 S Benedini , G Perseghin , I Terruzzi , et al. (2009) Effect of l-acetylcarnitine on body composition in HIV-related lipodystrophy. Horm Metab Res 41, 840–845.
252 A Balasubramanyam , I Coraza , EO Smith , et al. (2011) Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of “heart positive,” a randomized, controlled trial. J Clin Endocrinol Metab 96, 2236–2247.
256 E Razzini & GF Baronzio (1993) Omega-3 fatty acids as coadjuvant treatment in AIDS. Med Hypotheses 41, 300–305.
258 DA Wohl , HC Tien , M Busby , et al. (2005) Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis 41, 1498–1504.
260 R Manfredi , L Calza & F Chiodo (2004) Polyunsaturated ethyl esters of n-3 fatty acids in HIV-infected patients with moderate hypertriglyceridemia: comparison with dietary and lifestyle changes, and fibrate therapy. J Acquir Immune Defic Syndr 36, 878–880.
261 J Baril , CM Kovacs , S Trottier , et al. (2007) Effectiveness and tolerability of oral administration of low-dose salmon oil to HIV patients with HAART-associated dyslipidemia. HIV Clin Trials 8, 400–411.
263 MK Hellerstein , K Wu , M McGrath , et al. (1996) Effects of dietary n-3 fatty acid supplementation in men with weight loss associated with the acquired immune deficiency syndrome: relation to indices of cytokine production. J Acquir Immune Defic Syndr Hum Retrovirol 11, 258–270.
265 N Virgili , M Farriol , JM Castellanos , et al. (1997) Evaluation of immune markers in asymptomatic AIDS patients receiving fish oil supplementation. Clin Nutr 16, 257–261.
266 L Normén , B Yip , J Montaner , et al. (2007) Use of metabolic drugs and fish oil in HIV-positive patients with metabolic complications and associations with dyslipidaemia and treatment targets. HIV Med 8, 346–356.
268 SM Weldon , AC Mullen , CE Loscher , et al. (2007) Docosahexaenoic acid induces an anti-inflammatory profile in lipopolysaccharide-stimulated human THP-1 macrophages more effectively than eicosapentaenoic acid. J Nutr Biochem 18, 250–258.
270 C Pichard , P Sudre , V Karsegard , et al. (1998) A randomized double-blind controlled study of 6 months of oral nutritional supplementation with arginine and Ω-3 fatty acids in HIV-infected patients. Swiss HIV Cohort Study. AIDS 12, 53–63.